NCT01685996View on ClinicalTrials.gov

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Nicotine Dependence
Interventions
DRUG

zonisamide

In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline

DRUG

placebo

Trial Locations (1)

21224

Behavioral Pharmacology Research Unit, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT01685996 - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation | Biotech Hunter | Biotech Hunter